JPMorgan said the implied net impact aligns with recent commentary from Novo Nordisk, Teva and AbbVie during earnings season.

Novo Nordisk is chopping prices again for its popular obesity treatment Wegovy, but doctors say the expense will remain ...

The Centers for Medicare & Medicaid Services announced Nov. 25 that Medicare recipients will pay less for 15 prescription ...

For many years, the narrative surrounding obesity in the United States has been one of relentless increase. From the ...

Medicare announced 15 lower drugs after a second round of negotiations with pharmaceutical companies. The drugs include ...

The government said Tuesday that Novo Nordisk's (NVO) drugs - Ozempic and Rybelsus for Type 2 diabetes - will cost $274 for a month's supply in 2027 for people covered by Medicare. Wegovy, which is ...

The Trump administration announced Tuesday that there would be major savings coming to the federal government.

Novo Nordisk is seeking FDA approval for a 7.2 mg dose of Wegovy, nearly three times the current maximum dose. The ...

The Trump administration’s negotiation with Novo Nordisk A/S that slashes 71% off the list price of its blockbusters Ozempic ...

The Trump administration late Tuesday announced new lower Medicare prices for 15 drugs that were part of the latest round ...

The Trump administration tapped a Biden-era rule to negotiate lower prices on 15 widely used medications for seniors.

Medicare has negotiated steep new prices for 15 high-cost drugs, including Novo Nordisk’s blockbuster semaglutide (Wegovy and Ozempic), with negotiated prices set to take effect in 2027. The move cuts ...